Using a new treatment to fight lung infections caused by Pseudomonas aeruginosa in patients with bronchiectasis
Official title: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Funded at Vast Therapeutics, INC. · NIH-11065101 · Data updated 2026-11-12
This study is testing a new inhalable treatment for people with bronchiectasis who have tough lung infections caused by Pseudomonas aeruginosa, aiming to help them breathe better and reduce infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vast Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | December 20, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 1R44AI184225-01A1 |
| Project ID | NIH-11065101 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bronchiectasis who are experiencing recurrent infections caused by Pseudomonas aeruginosa.
✕Less likely to help
Patients who do not have bronchiectasis or are not infected with Pseudomonas aeruginosa may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for bronchiectasis patients suffering from Pseudomonas aeruginosa infections, which are known to cause severe respiratory issues. The approach involves using a nitric oxide-releasing prodrug that can be inhaled, allowing for targeted delivery of this antibacterial agent directly to the lungs. By addressing the challenges of antibiotic resistance and biofilm formation, this treatment aims to improve patient outcomes and reduce the frequency of infections. The study will evaluate the effectiveness of this new therapy in preclinical models before moving to clinical trials.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with chronic lung infections, potentially reducing morbidity and mortality associated with bronchiectasis.
How similar studies have gone: Preliminary studies have shown promise in using nitric oxide for treating bacterial infections, indicating potential success for this novel approach.
Where this research is happening
-
Vast Therapeutics, INC.
Morrisville, United States Active
Researchers
- Principal investigator: Stasko, Nathan Allan — Vast Therapeutics, INC.
- Study coordinator: Stasko, Nathan Allan
Related research
Other NIH-funded projects on the same topics.
-
A unifying mucus-driven paradigm for bronchiectasis in adults
A researchers-led program aims to better understand why bronchiectasis causes chronic cough and lung problems in adults and to explore new ways to treat it.
-
Bronchiectasis and COPD in Smokers: AI CT Tools and Proteomics to Predict Progression
This project uses AI-powered CT imaging and proteomics to understand how bronchiectasis progresses in adults who smoke and have COPD, with the goal of identifying who is at higher risk for worsening lung disease.
-
Nebulized NO-releasing therapy for Pseudomonas infections in bronchiectasis
A new inhaled nitric oxide–releasing treatment is being tested to help people with bronchiectasis who have lung infections from Pseudomonas bacteria.
-
Understanding how bronchiectasis progresses in smokers
This study is looking at how bronchiectasis gets worse over time in people who smoke, using smart imaging technology to find signs that could help predict changes in their lung health, with the goal of improving care for those dealing with this condition and COPD.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
Breathlessness in respiratory diseases: who feels it and why
This study tests how physiology, psychology, function, and breathing patterns relate to breathlessness in people with respiratory conditions compared with healthy controls.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.